This is in sharp contrast with neutrophils treated with higher dose LPS causing immune-suppression/pathogenic inflammation, with elevated levels of CD11b and shredding of CD62L (Appendix Fig. S1) Our data reveal that neutrophils programmed by low-dose LPS may preferentially adopt an immune-enhancing, yet less pathogenic inflammatory/immune suppressive phenotype amenable for effective host anti-tumor immune defense, without eliciting adverse inflammatory damage. The gene discussed is SELL; the disease is neoplasm.